Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
How did MoneyWorks4me help subscribers to buy Divis Lab at Rs. 629/ share in 2017?

News

Stay Updated! In The World Of Investments!
Sensex 61716.05 49.54 (-0.08%)

SMS Pharmaceuticals Latest News

23

Jul, 2020

SMS Pharmaceuticals submits annual secretarial compliance report

SMS Pharmaceuticals has submitted the Annual Secretarial Compliance Report issued by CSB Associates, C Sudhir Babu, Practicing Company Secretary in compliance with Regulation 24A of SEBI (LODR) Regulations, 2015 for...

Read More

09

Jul, 2020

SMS Pharmaceuticals informs about certificate

In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 ,SMS Pharmaceuticals has informed that it has forwarded a copy of the Certificate dated 7th July, 2020, received from Aar...

Read More

27

May, 2020

SMS Pharmaceuticals informs about annual disclosure

SMS Pharmaceuticals has informed that it has enclosed the annual disclosure under Regulation 3 1(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011 from Promoters of the Company dated May ...

Read More

23

Mar, 2020

SMS Pharmaceuticals hits upper circuit on Dalal Street

SMS Pharmaceuticals is currently trading at its upper circuit limit of Rs. 34.60, up by 5.75 points or 19.93% from its previous closing of Rs. 28.85 on the BSE.
<...

Read More

16

Mar, 2020

SMS Pharmaceuticals trades in green on the BSE

SMS Pharmaceuticals is currently trading at Rs. 31.35, up by 1.35 points or 4.50% from its previous closing of Rs. 30.00 on the BSE.

The scrip opened at Rs. 28.3...

Read More

12

Mar, 2020

SMS Pharmaceuticals shines on receiving EIR from USFDA for API facility in Andhra Pradesh

SMS Pharmaceuticals is currently trading at Rs. 35.30, up by 0.90 points or 2.62% from its previous closing of Rs. 34.40 on the BSE.

The scrip opened at Rs. 34.95 and has touched a ...

Read More

12

Mar, 2020

SMS Pharmaceuticals receives EIR from USFDA for API facility in Andhra Pradesh

SMS Pharmaceuticals has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its API facility situated at Kandivalasa, Andhra Pradesh. The USFDA had inspected th...

Read More

09

Mar, 2020

SMS Pharmaceuticals moves up as USFDA completes inspection at its exclusive testing facility

SMS Pharmaceuticals is currently trading at Rs. 38.15, up by 1.20 points or 3.25% from its previous closing of Rs. 36.95 on the BSE.

The scrip opened at Rs. 38.5...

Read More

09

Mar, 2020

USFDA completes inspection at SMS Pharmaceuticals’ exclusive testing facility

The United States Food and Drug Administration (USFDA) has successful completed regulatory inspection at SMS Pharmaceuticals’ exclusive testing facility during March 02, 2020 to March 06, 2020. The regulatory ...

Read More

06

Feb, 2020

Sms pharmaceuticals informs about newspaper publication

Sms pharmaceuticals has informed that the company has enclosed the copies of advertisement issued in newspapers on 4th February, 2020 in ‘Financial Express’ in English language and in ‘Andhra Prabha’ in ...

Read More

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback